Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments
© 2024 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association..
Overcoming resistance to immune checkpoint inhibitors is an important issue in patients with non-small-cell lung cancer (NSCLC). Transcriptome analysis shows that adenocarcinoma can be divided into three molecular subtypes: terminal respiratory unit (TRU), proximal proliferative (PP), and proximal inflammatory (PI), and squamous cell carcinoma (LUSQ) into four. However, the immunological characteristics of these subtypes are not fully understood. In this study, we investigated the immune landscape of NSCLC tissues in molecular subtypes using a multi-omics dataset, including tumor-infiltrating leukocytes (TILs) analyzed using flow cytometry, RNA sequences, whole exome sequences, metabolomic analysis, and clinicopathologic findings. In the PI subtype, the number of TILs increased and the immune response in the tumor microenvironment (TME) was activated, as indicated by high levels of tertiary lymphoid structures, and high cytotoxic marker levels. Patient prognosis was worse in the PP subtype than in other adenocarcinoma subtypes. Glucose transporter 1 (GLUT1) expression levels were upregulated and lactate accumulated in the TME of the PP subtype. This could lead to the formation of an immunosuppressive TME, including the inactivation of antigen-presenting cells. The TRU subtype had low biological malignancy and "cold" tumor-immune phenotypes. Squamous cell carcinoma (LUSQ) did not show distinct immunological characteristics in its respective subtypes. Elucidation of the immune characteristics of molecular subtypes could lead to the development of personalized immune therapy for lung cancer. Immune checkpoint inhibitors could be an effective treatment for the PI subtype. Glycolysis is a potential target for converting an immunosuppressive TME into an antitumorigenic TME in the PP subtype.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Cancer science - (2024) vom: 25. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fukuda, Hironori [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Immunotherapy |
|---|
| Anmerkungen: |
Date Revised 25.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1111/cas.16154 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370168666 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370168666 | ||
| 003 | DE-627 | ||
| 005 | 20240327000509.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240327s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cas.16154 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1349.xml |
| 035 | |a (DE-627)NLM370168666 | ||
| 035 | |a (NLM)38527308 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fukuda, Hironori |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. | ||
| 520 | |a Overcoming resistance to immune checkpoint inhibitors is an important issue in patients with non-small-cell lung cancer (NSCLC). Transcriptome analysis shows that adenocarcinoma can be divided into three molecular subtypes: terminal respiratory unit (TRU), proximal proliferative (PP), and proximal inflammatory (PI), and squamous cell carcinoma (LUSQ) into four. However, the immunological characteristics of these subtypes are not fully understood. In this study, we investigated the immune landscape of NSCLC tissues in molecular subtypes using a multi-omics dataset, including tumor-infiltrating leukocytes (TILs) analyzed using flow cytometry, RNA sequences, whole exome sequences, metabolomic analysis, and clinicopathologic findings. In the PI subtype, the number of TILs increased and the immune response in the tumor microenvironment (TME) was activated, as indicated by high levels of tertiary lymphoid structures, and high cytotoxic marker levels. Patient prognosis was worse in the PP subtype than in other adenocarcinoma subtypes. Glucose transporter 1 (GLUT1) expression levels were upregulated and lactate accumulated in the TME of the PP subtype. This could lead to the formation of an immunosuppressive TME, including the inactivation of antigen-presenting cells. The TRU subtype had low biological malignancy and "cold" tumor-immune phenotypes. Squamous cell carcinoma (LUSQ) did not show distinct immunological characteristics in its respective subtypes. Elucidation of the immune characteristics of molecular subtypes could lead to the development of personalized immune therapy for lung cancer. Immune checkpoint inhibitors could be an effective treatment for the PI subtype. Glycolysis is a potential target for converting an immunosuppressive TME into an antitumorigenic TME in the PP subtype | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a lung cancer | |
| 650 | 4 | |a molecular subtype | |
| 650 | 4 | |a tumor microenvironment | |
| 650 | 4 | |a tumor‐infiltrating lymphocyte | |
| 700 | 1 | |a Arai, Kosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Mizuno, Hideaki |e verfasserin |4 aut | |
| 700 | 1 | |a Nishito, Yukari |e verfasserin |4 aut | |
| 700 | 1 | |a Motoi, Noriko |e verfasserin |4 aut | |
| 700 | 1 | |a Arai, Yasuhito |e verfasserin |4 aut | |
| 700 | 1 | |a Hiraoka, Nobuyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Shibata, Tatsuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Sonobe, Yukiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kayukawa, Yoko |e verfasserin |4 aut | |
| 700 | 1 | |a Hashimoto, Eri |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Mina |e verfasserin |4 aut | |
| 700 | 1 | |a Fujii, Etsuko |e verfasserin |4 aut | |
| 700 | 1 | |a Maruyama, Toru |e verfasserin |4 aut | |
| 700 | 1 | |a Kuwabara, Kenta |e verfasserin |4 aut | |
| 700 | 1 | |a Nishizawa, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Mizoguchi, Yukihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshida, Yukihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Watanabe, Shun-Ichi |e verfasserin |4 aut | |
| 700 | 1 | |a Yamashita, Makiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kitano, Shigehisa |e verfasserin |4 aut | |
| 700 | 1 | |a Sakamoto, Hiromi |e verfasserin |4 aut | |
| 700 | 1 | |a Nagata, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Mitsumori, Risa |e verfasserin |4 aut | |
| 700 | 1 | |a Ozaki, Kouichi |e verfasserin |4 aut | |
| 700 | 1 | |a Niida, Shumpei |e verfasserin |4 aut | |
| 700 | 1 | |a Kanai, Yae |e verfasserin |4 aut | |
| 700 | 1 | |a Hirayama, Akiyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Soga, Tomoyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Tsukada, Keisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Yabuki, Nami |e verfasserin |4 aut | |
| 700 | 1 | |a Shimada, Mei |e verfasserin |4 aut | |
| 700 | 1 | |a Kitazawa, Takehisa |e verfasserin |4 aut | |
| 700 | 1 | |a Natori, Osamu |e verfasserin |4 aut | |
| 700 | 1 | |a Sawada, Noriaki |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Atsuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshida, Teruhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Yasuda, Kazuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ochiai, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Tsunoda, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Aoki, Kazunori |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer science |d 2003 |g (2024) vom: 25. März |w (DE-627)NLM12479498X |x 1349-7006 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:25 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cas.16154 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 25 |c 03 | ||